06 April 2021 : Original article
Intensified Endoscopic Evaluation for Biliary Complications After Orthotopic Liver Transplantation
Tim R. Glowka1ABCDEF*, Caroline Karlstetter1BCF, Tobias J. Weismüller2BCD, Tim O. Vilz1CD, Christian P. Strassburg2CD, Jörg C. Kalff1CD, Steffen Manekeller1ACDEFDOI: 10.12659/AOT.928907
Ann Transplant 2021; 26:e928907
Table 3 Complications and immunosuppressive regimens.
| No biliary complications | Biliary complications | P | |
|---|---|---|---|
| n=59 | n=43 | ||
| Bilirubin (mg/dl) first 30 days | |||
| Trough | 0.78 (0.52–1.12) | 1.02 (0.67–1.96) | |
| Peak | 8.25 (4.58–13.34) | 10.98 (8.02–22.95) | |
| Bile duct strictures | 41 (95%) | ||
| Anastomotic/nonanastomotic | 20 (46%)/21 (49%) | ||
| Biliary leakage | 7 (16%) | ||
| Early/late (>1 year) onset | 37 (86%)/6 (14%) | ||
| Postoperative hemorrhage | 12 | 7 (16%) | 0.6 |
| SSI superficial | 8 (14%) | 4 (9%) | 0.51 |
| SSI deep (subfascial) | 3 (5%) | 2 (5%) | 1.0 |
| Hepatic artery thrombosis | 1 (2%) | 3 (7%) | 0.31 |
| Primary nonfunction | 2 (3%) | 3 (7%) | 0.65 |
| Organ rejection | 4 (8%) | 7 (16%) | 0.2 |
| Pneumonia | 9 (15%) | 13 (30%) | 0.07 |
| Repeated surgery | 28 (47%) | 15 (35%) | 0.51 |
| Immunosuppressant* | |||
| Tacrolimus | 41 (69%) | 32 (74%) | 0.59 |
| Ciclosporin | 21 (36%) | 17 (40%) | 0.68 |
| CellCept | 22 (37%) | 23 (53%) | 0.1 |
| Everolimus | 17 (29%) | 11 (26%) | 0.72 |
| Data are expressed as number (%), or median (interquartile range). * Multiple responses possible. | |||